Last reviewed · How we verify
Zenapax®, CellCept® and prednisolone
This combination suppresses the immune system to prevent organ rejection after transplantation by blocking T-cell activation and proliferation while reducing corticosteroid-induced inflammation.
This combination suppresses the immune system to prevent organ rejection after transplantation by blocking T-cell activation and proliferation while reducing corticosteroid-induced inflammation. Used for Prevention of acute organ rejection in renal transplant recipients, Prevention of acute organ rejection in other solid organ transplants.
At a glance
| Generic name | Zenapax®, CellCept® and prednisolone |
|---|---|
| Sponsor | University of Oslo School of Pharmacy |
| Drug class | Immunosuppressive combination therapy |
| Target | IL-2 receptor (daclizumab); inosine monophosphate dehydrogenase (mycophenolate mofetil); glucocorticoid receptor (prednisolone) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | FDA-approved |
Mechanism of action
Zenapax (daclizumab) is a monoclonal antibody that blocks the IL-2 receptor on T cells, preventing their activation. CellCept (mycophenolate mofetil) inhibits inosine monophosphate dehydrogenase, selectively suppressing T and B cell proliferation. Prednisolone is a corticosteroid that broadly suppresses immune responses. Together, this triple therapy provides multi-targeted immunosuppression for transplant rejection prevention.
Approved indications
- Prevention of acute organ rejection in renal transplant recipients
- Prevention of acute organ rejection in other solid organ transplants
Common side effects
- Infection (bacterial, viral, fungal)
- Gastrointestinal disturbances (diarrhea, nausea)
- Leukopenia
- Tremor, headache
- Hyperglycemia
- Hypertension
Key clinical trials
- Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: